These early findings shaped the next step, which focused on making particles strong enough to handle injection forces. Building Flowable Particles for Real-World Injection Solid particles formed by ...
Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers. Background: The INSIGHT study evaluates feasibility ...
The U.S. FDA approved Merck & Co. Inc.’s Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection on Sept. 19, making it the first and only subcutaneously (SC)-administered immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results